In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), intratherapeutic dosimetry is mandatory for organs at risk (e.g. kidneys) and tumours. We evaluated commercial dosimetry software (Dosimetry Toolkit) using varying imaging scenarios, based on planar and/or tomographic data, regarding the differences in calculated organ/tumour doses and the use for clinical routines. A total of 16 consecutive patients with NENs treated by PRRT with Lu-177-DOTATATE were retrospectively analysed. Single-photon emission computed tomography (SPECT)/Iow-dose computed tomography (CT) of the thorax and abdomen and whole body (WB) scintigraphy were acquired up to 7 days p.i. (at a maximum of five imaging time points). ...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
Aim Peptide receptor radionuclide therapy (PRRT) with (177) Lu-HA-DOTATATE has evolved as a new path...
SUMMARY Neuroendocrine tumors are a heterogeneous group of tumors that derive from endocrine cells...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
Radiation dose to the kidneys (kidney dose) in 177Lu-DOTATATE - Peptide Receptor Radionuclide Therap...
Targeted radionuclide therapy has been shown to be one of the most effective treatment options for m...
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effect...
Abstract Background Recently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulat...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Peptide receptor radionuclide therapy (PRRT) shows promising results in the treatment of neuroendoc...
Abstract Background This study’s aim was to develop our dosimetric methodology using a commercial wo...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
Aim Peptide receptor radionuclide therapy (PRRT) with (177) Lu-HA-DOTATATE has evolved as a new path...
SUMMARY Neuroendocrine tumors are a heterogeneous group of tumors that derive from endocrine cells...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), i...
Radiation dose to the kidneys (kidney dose) in 177Lu-DOTATATE - Peptide Receptor Radionuclide Therap...
Targeted radionuclide therapy has been shown to be one of the most effective treatment options for m...
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effect...
Abstract Background Recently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulat...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Peptide receptor radionuclide therapy (PRRT) shows promising results in the treatment of neuroendoc...
Abstract Background This study’s aim was to develop our dosimetric methodology using a commercial wo...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
International audienceBackground: The number of SPECT/CT time-points is important for accurate patie...
Aim Peptide receptor radionuclide therapy (PRRT) with (177) Lu-HA-DOTATATE has evolved as a new path...
SUMMARY Neuroendocrine tumors are a heterogeneous group of tumors that derive from endocrine cells...